prostacyclin


Also found in: Medical, Acronyms, Wikipedia.

pros·ta·cy·clin

 (prŏs′tə-sī′klĭn)
n.
A prostaglandin produced in the walls of blood vessels that acts as a vasodilator and inhibits platelet aggregation.

prostacyclin

(ˌprɒstəˈsaɪklɪn)
n
(Biochemistry) biochem any of several prostaglandins produced in the blood vessels, causing vasodilation and inhibiting platelet aggregation

pros•ta•cy•clin

(ˌprɒs təˈsaɪ klɪn)

n.
a prostaglandin, C20H32O5, that specifically inhibits the formation of blood clots.
[1975–80; prosta (te) + cycl (ic) + -in1, on the model of prostaglandin]
References in periodicals archive ?
The global PAH market has been segmented into prostacyclin and prostacyclin analogs, ERAs, PDE-5 inhibitors, and sGC stimulators, based on the commercially-available drug classes, to treat PAH.
Infusion of prostacyclin following experimental brain injury in the rat reduces cortical lesion volume.
Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypoxaemia.
When endothelial damage occurs, the endothelium produces less nitric oxide and prostacyclin, which causes the sympathetic adrenergic vasoconstrictor tone to be unopposed, leading to increased vessel tone or vasospasm.
41) The potential effects of prostacyclin in cartilage have not been examined, although it is interesting to note that mice with a targeted deletion of the prostacyclin receptor experience reduced pain and inflammation.
COX pathway is responsible for transforming arachidonic acid to prostaglandins, prostacyclins and thromboxanes.
No is the predominant mediator in large conduit arteries, whereas EDHF and prostacyclin are more prominent in smaller vessels such as the mesenteric vessels, coronary arteries, and peripheral resistance vessels (Shimokawa et al.
Seventy-two percent of women with idiopathic PAH received advanced therapies, including prostacyclin analogs, bosentan, sildenafil, or nitric oxide.
The leading hypothesis involves the fact that the drug suppresses prostacyclin for about 12 hours.
The short-term (eight to 12 weeks) use of IV or injected prostacyclin has shown some benefits for treating pulmonary hypertension; however, evidence does not support its use on a long-term basis.
A variety of therapies have been used for lichen aureus, including topical steroids, topical pimecrolimus 1% cream (8), phototherapy (9), and systemic calcium dobesilate (10), as well as a combination of pentoxifylline and prostacyclin (11).